CEO, MitoRx Therapeutics. Pioneering therapeutics in mitochondrial-driven disease.
Joined June 2012
- Tweets 1,709
- Following 1,278
- Followers 1,180
- Likes 1,466
32 Photos and videos
Jon Rees PhD retweeted
#NEWS: Today we announced the enrollment of the first individual in a Phase 1 study evaluating ARQ-234, a potential biologic treatment for moderate to severe #AtopicDermatitis.
Learn more: arcutis.com/arcutis-begins-e…
#ClinicalDermatology
2
3
128
25 Aug 2025
13 years later... today (25th August 2025), Organox acquired for $1.5b by Terumo for their normothermic organ transplant technology.
15 Oct 2012
That's the great thing about Oxbridge, saw the future of liver transplantation on my way to another meeting: OrganOx
1
114
6 May 2025
Impressive to see $ARQT 169% total prescriptions growth in Q1 2025 vs. Q1 2024, and doubling of Arcutis' revenues year-on-year.
6 May 2025
#NEWS: Today, we announced #Q1 2025 financial results. Read our release for full details and business updates: investors.arcutis.com/news-r…
$ARQT
1
3
10
2,204
12 Mar 2025
MitoRx Therapeutics is presenting at #BIOEurope Spring 2025 sharing the latest data demonstrating weight loss with muscle preservation
63
7 Jan 2025
Mizuho's upgraded outlook for $ARQT takes the average one-year price target for Arcutis Biotherapeutics to $19.38, driving intraday gains above 7% fintel.io/sfo/us/arqt
229
13 Oct 2024
Thanks to @LongevityTech for highlighting the promise of MitoRx Therapeutics' technology in metabolic disease this week.
10 Oct 2024
MitoRx demonstrates mitochondrial therapy holds potential in metabolic disease...
Study shows #mitochondria-targeted donor therapy reduces #weightgain and protects against #muscleloss in mice
@MitoRxTheraLtd @BiotechJon
#longevity #obesity #biotech #GLP1
longevity.technology/news/mi…
98
Jon Rees PhD retweeted
9 Jul 2024
📢Passionate about making a difference?
We're looking for a dedicated and motivated CEO to lead our national charity supporting PKD patients, carers, and renal clinicians.
Join us in our mission to improve lives. Find out more and apply:pkdcharity.org.uk/about-us/v…
4
6
586
Jon Rees PhD retweeted
7 Mar 2024
We’ve appointed 4 additional experts @oligogirl @HansbroResearch @CarolineGuiner @MilosFi37777561 to our SAB, to support developing treatments for degenerative diseases with the world's only mitochondrial platform restoring sulfide-signaling. @biotechjon
tinyurl.com/4vaamzpj
3
5
285
3 Mar 2024
I was deeply saddened about the passing of Tess Harris, PKD Charity UK CEO. PKD is one of the most common genetic diseases affecting up to 70,000 people in UK, 600,000 in the US and 12 million worldwide, but remains grossly underserved by our industry. Let's change that.
3 Mar 2024
💜With profound sorrow, we announce the passing of our beloved CEO, Tess Harris, peacefully on March 1, 2024.
A tireless advocate for PKD, her visionary leadership and dedication will forever inspire us.💜
Full statement: bit.ly/TessPKD
2
141
Jon Rees PhD retweeted
26 Feb 2024
@BiotechJon will share insights at #BIOEuropeSpring into our first-in-class mitochondriotropic therapeutics, now validated preclinically in mammalia. These restore sulfide-signalling, which can arrest progression in degenerative conditions.
🤝 Book a mtg: lnkd.in/e2EQTn8j
1
1
70
1 Jan 2024
Looking forward to sharing positive preclinical results from MitoRx's programs modulating mitochondrial dysfunction to arrest decline in degenerative diseases at #JPM24 next week...
18 Dec 2023
@Biotechjon is at #BiotechShowcase2024 on Jan 8-9, presenting our groundbreaking therapeutic pipeline targeting mitochondria dysfunction in rare diseases like #Duchenne & #Huntingtons. Hear about our promising preclinical results and recent financing news! tinyurl.com/27ry4v89
2
418
28 Nov 2023
Preprint alert: Vignane shows oxidation of cysteine residues promotes aberrant LLPS and aggregation (seen in ND) and cysteine persulfidation prevents this. Protective persulfidation is impaired in neurodegeneration, MitoRx restores this. 1 minute summary:
sciencecast.org/casts/avlou2…
1
1
134
Jon Rees PhD retweeted
7 Aug 2023
Really interesting paper validating @MitoRxTheraLtd technology. Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treated Caenorhabditis elegans | PNAS pnas.org/doi/abs/10.1073/pna…
2
2
216
10 Jul 2023
Over 60% of FDA-approvals of new drugs from the top 20 pharma originate externally (including 6% from collaboration). And only 3% originate in Universities. Read that last bit again. Tell everyone you know this: biotech is the crucible for innovation.
5 Jul 2023
Investigating the origins of recent pharmaceutical innovation bit.ly/3D22C9q
An analysis of new drugs from the top 20 biopharma companies indicates that their business model in recent years has largely been built on external innovation, as only 28% originated internally
126
Jon Rees PhD retweeted
13 Mar 2023
Silicon Valley Bank UK has today been sold to @HSBC.
This transaction has been facilitated by the @bankofengland in consultation with HM Treasury.
No taxpayer money is involved and customer deposits have been protected.
Find out more ⬇️
gov.uk/government/news/gover…
127
357
767
625,331
12 Mar 2023
The Fed and Treasury have set the bar: backstoping all SVB US depositors. EB-5 green card option will look attractive if tomorrow the UK falls short on backstoping SVB UK depositors who underpin our knowledge economy @Jeremy_Hunt @hmtreasury @griffitha
home.treasury.gov/news/press…
1
288
8 Mar 2023
Proud to lead the growing MitoRx team pioneering the development of a unique technology to tackle mitochondrial-driven disease.
7 Mar 2023
We’re delighted to welcome Christine Charman as Chief Development Officer and David Richardson as Finance Director. We also have our new Scientific Advisory Board with Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.
82
21 Nov 2022
The #AutumnStatement cuts to the SME R&D tax credit incentive halving its value to venture-backed biotech is a mistake. Hard to reconcile this with the stated ambition to increase total R&D investment to 2.4% of GDP by 2027. Retweet if you support a rethink @GeorgeFreemanMP
21 Nov 2022
I fully share and support the concerns raised by our friends at @BIA_UK on how the cuts to SME R&D tax credits will damage the competitiveness of this vital part of #UKLifeSciences We have to make sure the whole ecosystem is firing on all cylinders to realise growth potential
1